In vivo Pharmacology Studies

We offer in vivo pharmacology studies in nearly 50 animal models to mimic conditions of the human eye.

Iris Pharma offers nearly 50 in vivo animal models – the largest number on the market – to mimic conditions of the human eye. Not only do we help clients select the appropriate in vivo efficacy model, but we can also develop new animal models as needed, according to the specific requirements of our clients.

We use state-of-the-art ocular technology – including Spectralis® HRA+OCT, confocal microscopy, tomography, electroretinography, and more – to demonstrate the efficacy of particular ophthalmic drugs or devices.

Angiogenesis & Permeability

Ocular angiogenesis & retinal vascular permeability models:

  • CORNEAL neovascularization: sutures or alkali burn
  • CHOROIDAL neovascularization: experimental argon laser-induced choroidal neovascularization (CNV model)
  • RETINAL neovascularization: animal model of oxygen-induced retinopathy (OIR)
  • RETINAL vascular permeability: VEGF-induced retinal vascular permeability model

Applications:

  • Proof of concept for angiogenesis and/or lymphangiogenesis
  • Corneal angiogenesis:
    • inflammatory disorders
    • stromal ulceration
    • corneal graft
    • infectious keratitis
  • Choroidal angiogenesis: wet age-related macular degeneration (AMD)
  • Retinal angiogenesis:
    • diabetic retinopathy
    • retinopathy of prematury (ROP)
    • ischemic retinopathies

Evaluations:

  • Length of new vessels and network density
  • Lesion volume (optical coherence tomography (OCT)
  • Angiography (HRA)
  • Histology (number of new vessels ...)
  • Retina examination (fundus, HRT)
  • Corneal examination (HRT)
  • Visualization and quantification of size of the lesion in the CNV model (flatmount evaluation)
  • Marker levels

Ocular angiogenesis & retinal vascular permeability publications:

The Uni-Nephrectomized SDT Fatty Rat, a novel Type 2 diabetic model of Diabetic Nephropathy, develops features of diabetic retinopathy over 10 weeks

BRIAND F et al. ARVO meeting 2018; Hawaii - USA. Abstract No. 3573 - A0190     Poster     Abstract

SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model

ELENA PP et al. EVER meeting 2016; Nice – France    Poster    Abstract

Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization

KLAR J et al. ARVO meeting 2015; DENVER, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56(7): 426.92   Abstract

Ether-lipid-deficient-mice display pigmentary glaucoma features as well as abnormal retinal vasculature

ACAR N et al. ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. May 2007, Vol.48, 2978. doi: Abstract

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation

JENSEN L et al. 8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21   Abstract

Effects of Dexamethasone in a Rat model of choroidal neovascularization

FERAILLE L et al. Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom   Poster

Variation of Krüppel-like factors levels in mouse corneal model of angiogenesis

CHIAMBARETTA F et al. ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609

Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis

CHIAMBARETTA F et al. SFO meeting 2005; Paris – France. Abstract No. 380

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hypoxic stimuli

ELENA PP et al. ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053   Abstract

PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice

CAILLAUD T et al. ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062   Abstract

 

ocular angiogenesis

Ocular Neurodegeneration

ocular neurodegeneration

Ocular neurodegeneration models:

  • Retinal ganglion cell (RGC) loss in optic nerve clamping model
  • RGC loss in model of elevated intraocular pressure
  • RGC loss in model of NMDA-mediated excitotoxic damage
  • Photoreceptor apoptosis in animal model of blue light damage (LD) retinal degeneration 

Applications:

  • Dry age-related macular degeneration (dry AMD)
  • Geographic atrophy
  • Glaucoma
  • Central retinal artery or vein occlusion (CRAO, CRVO)
  • Diabetic retinopathy
  • Retinal ischemia

Evaluations:

  • Electroretinography (ERG)
  • Optical coherence tomography (OCT)
  • Fundus autofluorescence (FAF) imaging
  • RGC density (histological analysis)

Ocular neurodegeneration publications:

The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks

BRIAND F et al. ARVO meeting 2018; Hawaii - USA. Invest. Ophthalmol. Vis. Sci. 2018; 59(9):3573. doi:   Poster     Abstract

Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration

ELENA PP et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):4532. doi:  Abstract

Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo

FONTAINE V et al. PLOS ONE 11(12): e0167793. doi:10.1371/journal.pone.0167793  Article

BIO201: a new drug candidate for the treatment of dry AMD

FONTAINE V et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12):1119. doi: Abstract

Protection of blue light induced retinal degeneration by the free radical scavenger Phenyl-N-tert-butylnitrone and a serotonin receptor 5-HT1a agonist in rats

GRILLO-ANTONELLI S et al. EVER meeting 2012; Nice - France. Poster S063  Poster  Abstract

Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats

ELENA PP et al. EVER meeting 2012; Nice - France. Poster F029  Abstract

Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat

FREDJ-REYGROBELLET D et al. ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39:S993

Retinal damage and protection after ischemic injury in the rat: a reappraisal

ELENA PP et al. ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38:S888

Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat

MOREL MANDRINO P and al. ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38:S103

Histological and cytological retinal changes after pressure-induced ischemia in rat eye

FREDJ-REYGROBELLET D et al. Vision Res. 1996;36:S220

 

Ocular Hypertension & Glaucoma

Ocular hypertension models:

  • Steroid-induced ocular hypertension
  • Hypertonic saline-induced ocular hypertension
  • Water loading-induced ocular hypertension
  • Normotensive

Applications:

  • Ocular hypertension
  • Primary open-angle glaucoma (POAG)

Evaluation: 

  • Intraocular pressure (IOP) measurement (tonometry)

Ocular hypertension publications:

Comparison of the effect of Dexamethasone and Prednisolone Acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery

ELENA PP et al. ARVO meeting 2015; DENVER, CO - USA. Invest. Ophthalmol. Vis. Sci. 2015; 56(7 ):2001. doi:  Abstract

Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma

GRILLO-ANTONELLI S et al. EVER meeting 2014; Nice – France. Poster T017  Poster   Abstract

Assessment of Intra-Ocular Pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery

GOODY RJ et al. ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D812  Abstract

Immunohistochemistry and in situ zymography to assess matrix metalloproteinases expression and activation by latanoprost in rat uveoscleral pathway

ELENA PP et al. ARVO meeting 2008; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2008, Vol.49, 2616. doi:  Abstract

Ether-lipid-deficient-mice display pigmentary glaucoma features as well as abnormal retinal vasculature

ACAR N et al. ARVO meeting 2007; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. May 2007, Vol.48, 2978. doi: Abstract

Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits

FLEISCHHAUER JC et al. Klin. Monatsbl. Augenheidkd. 2001; 218: 351-353  Abstract

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

ELENA PP et al. ARVO meeting 2001; Fort Lauderdale, FL - USA. Abstract No. 2915

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension

LACHERETZ F et al. J. Ocul. Pharmacol. Ther. 2000; 16: 203-216  Abstract

Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits

PISELLA PJ et al. Ophthalmic Res. 2000; 32: 3-8  Article

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter

TISSIE G et al. EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit

SERRADEIL-LE GAL C et al. World Congress on Neurohypophysial Hormones. 1999; Edinburgh - UK

The effect of pneumoperitoneum on intraocular pressure in rabbits with α-chymotrypsin-induced glaucoma

LENTSCHENER C et al. Anesth. Analg. 1998; 86: 1283-1288. (collaboration)

Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma

LACHERETZ F et al. ISER 1998 Abstract No. 795; Paris – France. Exp. Eye Res. 1998; 67: S239

Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP et al. ISECOPP meeting 1997 Munich – Germany, p. 12

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits

TILLEUL P et al. Ophthalmic Res. 1997; 29: 218-226  Abstract

Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits

AMAR T et al. ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790

Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects

NORDMANN JP et al. ISECOPP meeting 1995; Geneva – Switzerland, p. 35

Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits

DENIS P et al. ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 925, abstract No. 1115.

Graph legend: Reduction of experimentally induced elevated intraocular pressure (IOP)

ocular hypertension

Ocular Allergy

Ocular allergy

Ocular allergy models:

  • Ovalbumine-induced allergic conjunctivitis (early phase and/or late phase)
  • Compound 48/80-induced ocular conjunctivitis model
  • Histamine-induced ocular conjunctivitis
  • Ragweed-induced allergic conjunctivitis

Application:

  • Seasonal allergic conjunctivitis

Evaluations:

  • Clinical scoring
  • Slip Lamp ocular examination: clinical evaluation
  • Spectrophotometry: extravasation of a dye in eyelids / eyeball or in aqueous humor / iris ciliary body
  • HRTII, histology: cellular infiltration
  • Mediator concentration

Ocular allergy publications:

New evaluation techniques in ocular surface diseases : comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig

FERAILLE L. Oral presentation. EVER meeting 2007; Portoroz, Slovenia

Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis

ELENA PP et al. ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis

ELENA PP et al. ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models

ELENA PP et al. ISECOPP meeting 1995 Geneva - Switzerland, p. 60

Allergic conjunctivitis and uveitis models: Reappraisal with some marketed drugs

KHOSRAVI E et al. Inflamm. Res. 1995; 44: 47-54. Abstract

Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye

LAPALUS P et al. Curr. Eye Res. 1986; 5: 517-522.

 

Ocular Inflammation

Ocular inflammation models:

  • Endotoxin-Induced Uveitis (EIU) (LPS model of inflammation)
  • Intraocular surgery and cataract surgery (phacoemulsification or intra/extracapsular)
  • AH paracentesis
  • Experimental Autoimmune Uveitis (EAU)
  • Mycobacteruim Tuberculosis

Applications:

  • Acute anterior uveitis
  • Posterior and panuveitis
  • Acute ocular inflammation resulting from exogenous injuries either post ocular surgery or due to accidents

Evaluations:

  • Protein concentration in the aqueous humor
  • Spectrophotometry: extravasation of a dye in conjunctiva
  • Clinical scoring (conjunctival swelling)
  • Mediator concentration (prostaglandin, leukotriene, interleukin or other)
  • Laser flare meter
  • Slit lamp ocular examination

Ocular inflammation publications:

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops

DAULL P et al. Curr. Eye Res. 2019 Jan 21:1-10. doi:10.1080/02713683.2018.1563197 Abstract

Chronic model of uveitis in rabbit - Efficacy of Triamcinolone Acetonide

QUENTRIC Y et al. ARVO meeting 2019; Vancouver - CANADA. Abstract No. 800 - B0278   Poster

Comparison of inflammatory gene networks in dry eye between human and mouse

KESSAL K et al. ARVO meeting 2019; Vancouver - CANADA. Abstract No. 274 - B0413 Abstract

Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye

GARRIGUE JS et al.  ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi:    Abstract

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P et al. J. Ocul. Pharmacol. Ther. 2016; DOI: 10.1089/jop.2015.0054.  Article

Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation

DAULL P et al. IOIS meeting 2015; San Francisco – USA

Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation

Invest. Ophthalmol. Vis. Sci 2014; 55: 2859. doi: (collaboration)  Article

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P et al. EVER meeting 2012; Nice - France. Poster T036   Abstract

Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration

ELENA PP et al. ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D1145    Poster    Abstract

Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits

CAILLAUD T et al. ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957  Poster

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation

JENSEN L et al. 8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21   Abstract

Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy

BAUDOUIN C et al. Ophthalmic Res. 1998; 30: 340-350    Abstract

Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne

PISELLA PJ et al. Ophtalmologie (France) 1997; 11: 369-371

 

ocular inflammation

Dry Eye Syndrome

dry eye syndrome

Dry eye syndrome models:

  • Extraorbital lacrimal gland excision
  • Scopolamine-induced dry eye syndrome
  • Controlled-environmental conditions and scopolamine-induced dry eye syndrome

Applications:

  • Dry eye syndrome (DES)
  • Keratoconjunctivitis sicca (KCS)

Evaluations:

  • Corneal staining (fluorescein test)
  • Tear volume (phenol red threat (PRT) tear test)
  • Histology analysis
  • Bioassays

Dry eye syndrome publications:

Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops

DAULL P et al. Curr. Eye Res. 2019 Jan 21:1-10. doi: 10.1080/02713683.2018.1563197 Abstract

Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye

DAULL P et al. ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):292. doi: Abstract

Dry Eye: Efficacy evaluation of two synthetic peptides from Chondrocyte Derived ExtraCellular Matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye

BAIK T et al. ARVO meeting 2019; Vancouver - Canada. Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):291. doi: Abstract

Comparison of inflammatory gene networks in dry eye between human and mouse

KESSAL K et al. ARVO meeting 2019; Vancouver - Canada. Abstract No. 274 - B0413 Abstract

Safety and tolerability of overdosed artificial tears by abraded rabbit corneas

DAULL P et al. J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040 Abstract

Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye

GARRIGUE JS et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):800. doi: Abstract

Corneal transcriptome changes in a mouse model of dry eye

DAULL P et al. ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8):797. doi: Abstract

Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye

DAULL P et al. Exp. Eye Res. 2016 Oct 21; 153:159-164 Full article

Comparative efficacy of cyclosporine eye drop formulations in a mouse model of dry eye

GARRIGUE JS et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):421. doi: Abstract

Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye

QUENTRIC Y et al. ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. Sept. 2016, Vol.57, 422. doi: Poster Abstract

HL036337 ophthalmic solution: topical TNF blocker for dry eye disease

Protein and AntiboPEGS meeting 2015 Boston, MA (collaboration)

Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye

CIMBOLINI N et al. EVER meeting 2015; Nice – France. Poster T031 Poster

Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye

DAULL P et al. ARVO meeting 2015; Denver, CO - USA. Invest. Ophthalmol. Vis. Sci. June 2015, Vol.56, 4468. doi: Abstract

The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S et al. Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548 Article

Dry eye: two experimental rodent models for drug development

CIMBOLINI N et al.TFOS meeting 2013; Taormina - Sicily – Italy Poster

Effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N et al. EVER meeting 2013; Nice – France. Poster S008 Poster Abstract

Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye

CIMBOLINI N et al. ISOPT meeting 2013; Paris – France Poster

Comparison of two rodent models of dry eye induced by scopolamine

ELENA PP et al. ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065 Abstract

Potency and duration of action of synthetic P2Y2 receptor agonists on schirmer scores in rabbits

YERXA BR et al. Adv. Exp. Med. Biol. 2002; 506: 261-265 Abstract

Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits

YERXA BR et al. 3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI – USA - Cornea 2000; 19: S138

INS365, a P2Y2 receptor agonist, increases schirmer scores in albino rabbits

YERXA BR et al. ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848

 

Corneal Wound Healing

corneal wound healing

Corneal wound healing models:

  • Surface damage: corneal epithelium debridement induced by mechanical or chemical means
  • Depth damage: manual superficial keratectomy

Application:

  • Corneal wound healing delay
  • Neurotrophic keratitis
  • Corneal fibrosis syndrome
  • Persistent corneal epithelial defects (PCED)

Evaluations:

  • Fluorescein test
  • Histology analysis
  • Image analysis

Corneal wound healing publications:

Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas

DAULL P et al. J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040 Abstract

Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing

DAULL P et al. EVER meeting 2015; Nice – France. Poster T034 Abstract

Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping

DAULL P et al. J. Ocul. Pharmacol. Ther. 2016; DOI: 10.1089/jop.2015.0054  Article

Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping

DAULL P et al. EVER meeting 2012; Nice - France. Poster T037 Abstract

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes

KHOSRAVI E et al. ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383.

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

CHIBRET H et al. ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712.

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye

FREDJ-REYGROBELLET D et al. Curr. Eye Res.1989; 8: 1141-1152.

Graph legend: Rate of corneal wound healing after complete deepithelialization and daily instillation

 

 

 

 

Ocular Pain

Ocular pain or discomfort models:

  • Capsaicin-induced ocular pain
  • Formalin-induced eye discomfort

Applications:

  • Ocular pain
  • Ocular discomfort

Evaluations:

  • Mesurement of the palpebral opening
  • Observing the conjunctival hyperemia
  • Eyelid blinking rate
  • Corneal anesthesia measurement

Ocular Surgery

Ocular surgery models:

  • Phacoemulsification
  • Keratecomy
  • Paracentesis
  • Device implantation
  • Others

Ocular surgery publications:

Safety evaluation of cationic emulsions following refractive surgery procedures

QUENTRIC Y et al. ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250    Abstract

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies

FUCHS H et al. J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)

Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M et al. ARVO meeting 2014; Orlando, FL - USA. Invest. Ophthalmol.Vis. Sci 2014; 55, 5273. doi: Abstract

Hymecel pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits

ELENA PP et al. AER meeting 1990, Bad Honnef - Germany, p 25, abstract No. 6.